$0.69
-0.05 (-6.91%)
Open$0.73
Previous Close$0.74
Day High$0.74
Day Low$0.69
52W High$8.81
52W Low$0.62
Volume—
Avg Volume35.3K
Market Cap16.63M
P/E Ratio—
EPS$-7.35
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,564.3% upside
Current
$0.69
$0.69
Target
$11.50
$11.50
$7.99
$11.50 avg
$12.09
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 25.40M | 987.4K | 951.3K |
| Net Income | -2,590,448,648 | -74,062 | -66,038 |
| Profit Margin | -374.3% | -7.5% | -6.9% |
| EBITDA | -2,510,536,211 | -123,235 | -109,691 |
| Free Cash Flow | — | -44,936 | -40,091 |
| Rev Growth | — | +23.6% | +13.9% |
| Debt/Equity | 0.01 | 1.06 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |